Smallpox virus destruction and the implications of a new vaccine

Biosecurity and Bioterrorism

Volumn 9, Issue 2, 2011, Pages 163-168

  Henderson, D A ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SMALLPOX VACCINE;

DRUG APPROVAL; ECONOMICS; HEALTH CARE FACILITY; HUMAN; LEGAL ASPECT; MANAGEMENT; MEDICAL RESEARCH; REVIEW; SMALLPOX; SMALLPOX VIRUS;

BIOLOGICAL SPECIMEN BANKS; BIOMEDICAL RESEARCH; DRUG APPROVAL; HUMANS; POLICY MAKING; SMALLPOX; SMALLPOX VACCINE; VARIOLA VIRUS;

VARIOLA VIRUS;

EID: 79957775219     PISSN: 15387135     EISSN: None     Source Type: Journal    
DOI: 10.1089/bsp.2011.0011     Document Type: Review

References (18)

1. World Health Organization. Report of the Meeting of the Ad Hoc Committee on Orthopoxvirus Infections. WHO Document no. WHO/CDS/BVI/94.3. Geneva, Switzerland, September 9, 1994.
2. Baltimore D. Smallpox virus stocks. Science 1994;263:13.
3. Tucker JB. Breaking the deadlock over destruction of the smallpox virus stocks. Biosecur Bioterror 2011;9(1). epub ahead of print.
4. World Health Organization. Scientific review of variola virus research, 1999-2010. Geneva: WHO; December 2010.
5. World Health Organization. Advisory Group of Independent Experts to review the smallpox research programme (AGIES): Comments on the Scientific Review of Variola Virus Research, 1999-2010. WHO Document no. WHO/HSE/GAR/BDP/ 2010.4. Geneva: WHO; December 2010.
6. World Health Organization. WHO Advisory Committee on Variola Virus Research: Report of the Twelfth Meeting, Geneva, Switzerland 17-18 November 2010. WHO Document no. WHO/HSE/GAR/BDP/2010.5. Geneva: WHO; 2010.
7. World Health Organization. Report of the Meeting of the Ad Hoc Committee on Orthopoxvirus Infections. Geneva, Switzerland, 14 January 1999. WHO Document no. WHO/ CDS/CSR/99.1. Geneva: WHO; 1999.
8. Monath TP, Caldwell JR, Mundt W. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)-a second-generation smallpox vaccine for biological defense. Int J Infect Dis 2004 Oct;8 Suppl 2:S31-S44. (Pubitemid 39445966)
9. Saito T. Research on preparedness for bioterorism-associated events in Japan: smallpox vaccine preparedness. Journal of Disaster Research 2009;4:329-336.
10. von Krempelhuber A, Vollmar J, Pokorny R, et al. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine 2010 Feb 3;28(5):1209-1216.
11. DiMasi JA, Grabowski HG, Vernon J. R&D costs and returns by therapeutic category. Drug Information Journal 2004;38:211-223. (Pubitemid 39121144)
12. Henderson DA, Inglesby TV, Bartlett JG, et al. Smallpox as a biological weapon: Medical and public health management. Working Group on Civilian Biodefense. JAMA 1999 Jun 9;281(22):2127-2137. (Pubitemid 29264692)
13. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: Results of ten statewide surveys. J Infect Dis 1970;122:303-309.
14. Military Vaccine Agency and the Vaccine Healthcare Centers Network. Used with permission.
15. Jordan R, Chinsangaram J, Bolken TC, et al. Safety and pharmacokinetics of the antiorthopoxvirus compound ST- 246 following repeat oral dosing in healthy adult subjects. Antimicrob Agents Chemother 2010 Jun;54(6):2560-2566.
16. Lanier R, Trost L, Tippen T, et al. Development of CMX001 for the treatment of poxvirus infections. Viruses 2010;2(12):2740-2762.
17. IMVAMUNE. MVA-BN® based, third-generation smallpox vaccine candidate. Bavarian-Nordic. http://www.bavariannordic. com/pipeline/imvamune-smallpox- vaccine.aspx. Accessed March 8, 2011.
18. Arita I. Smallpox vaccine and its stockpile in 2005. Lancet Infect Dis 2005 Oct;5(10):647-652. (Pubitemid 41383910)